NCT00387803

Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation

VENTAK CHF/CONTAK CD Biventricular Pacing Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 581 (planned)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.

Detailed description

Patients enrolled received a device with cardiac resynchronization therapy (CRT) and defibrillation. Patients were randomized to CRT on or off for up to six months and evaluated for mortality, hospitalization, and functional outcomes including exercise capacity, quality of life, symptomatic status, and echocardiographic analysis.

Conditions

• Heart Failure, Congestive
• Ventricular Fibrillation
• Tachycardia, Ventricular

Interventions

Type	Name	Description
DEVICE	Cardiac Resynchronization Therapy with Defibrillation

Timeline

• Start date: 1998-02-01
• Completion: 2001-08-01
• First posted: 2006-10-13
• Last updated: 2007-01-25

Locations

1 site across 1 country: United States